Nuvalent (NUVL) is trading higher as investors react to fresh partnership news and a near-term catalyst calendar. The latest headline is a multi-year strategic collaboration with Guardant Health to develop companion diagnostics and support clinical development and potential commercialization using Guardant’s Infinity platform, a development that can reduce friction around biomarker testing and launch-readiness for targeted oncology drugs. (investors.guardanthealth.com)

For targeted cancer therapies, uptake often depends on identifying the right patients quickly and reliably. A dedicated companion diagnostic strategy—spanning tissue and liquid biopsy options and global commercialization planning—can be viewed as de-risking steps that sit downstream of clinical efficacy, particularly as programs move closer to potential approvals and broader commercial buildout. (investors.guardanthealth.com)

Nuvalent has another high-visibility event on the horizon: an oral presentation at the 2026 ASCO Annual Meeting (May 29–June 2, 2026, Chicago) featuring pivotal data from the ALKOVE-1 trial for neladalkib in TKI pre-treated advanced ALK-positive NSCLC, plus additional program updates. Separately, the company is expected to report Q1 2026 results before the market opens on May 7, 2026, giving traders another near-term check-in on cash burn, timelines, and regulatory execution. (prnewswire.com)

Key swing factors over the next several weeks include (1) any new detail on which specific Nuvalent studies the Guardant diagnostics will support and how that aligns with potential launch sequencing, (2) ASCO abstract details and investor interpretation of efficacy/safety and CNS activity for neladalkib, and (3) management commentary around regulatory timelines, including previously disclosed FDA review timing for zidesamtinib. (stocktitan.net)